Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Extracorporeal Shock Waves Therapy for the Treatment of Acute and Chronic Wounds-A Prospective, Monocentric Clinical Trial to Examine the Effect of Shock Waves on Wound Healing.
Health Sci Rep
January 2025
Department of Plastic, Reconstructive and Aesthetic Surgery, Hand Surgery Martin-Luther Hospital (Martin-Luther Krankenhaus) Berlin Germany.
Introduction: The aim of our prospective blinded clinical study was to examine a possible improvement and acceleration of epithelialization by treatment with low-energy extracorporeal shock waves on skin graft donor and recipient sites in patients with chronic wounds. In addition, several secondary parameters were investigated to evaluate the compatibility of the therapeutic method, its influence on infection occurrence and bacterial colonization.
Materials And Methods: A total of 35 patients were included in the study.
Background: Mobile phlebotomy is an attractive option for the study of Alzheimer's disease (AD) in rural and underserved populations, but logistics of collecting, and shipping these samples outside clinical settings can introduce additional sources of variability. Knowledge is limited on the impact of field collection on blood-based Alzheimer's disease biomarkers, especially protein stability when dry ice is not available during shipping. Our study looks into the effects of holding plasma samples under refrigeration prior to freezing on AD biomarker concentrations compared to samples that were frozen within one hour of collection as is standard practice.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Africa Mental Health Research and Training Foundation, Nairobi, Kenya.
Background: Plasma/serum measurements, which stand as the clinical gold standard biomarkers for Alzheimer's disease (AD) are minimally invasive, facilitating easy collection and processing particularly in low-resource settings. Often, both laboratory and non-laboratory medical personnel find themselves collecting these blood biomarker samples in remote hospitals characterized by a high influx of patients, leaving them with limited time and resources (e.g.
View Article and Find Full Text PDFBackground: New disease modifying treatments for Alzheimer's Disease (AD) require confirmation of amyloid biomarkers and evidence of clinical and/or cognitive AD symptoms. Blood tests for AD biomarkers are poised to enter routine care. However, at-risk individuals with positive biomarkers vary in their level of cognitive impairment, raising the need for sensitive and scalable cognitive assessments.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Brain and Spine Surgeons of Orange County, Newport Beach, CA, USA.
Background: It has been more than 20 years for a new treatment for Alzheimer's Disease (AD) to emerge. This treatment has recently been in the form of a monoclonal antibody targeting the end-products of neuronal death. We are testing the safety of a novel approach using activated stem cells injected directly into the ventricles of the brain.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!